Cryo-EM structures of inhibitory antibodies complexed with arginase 1 provide insight into mechanism of action

Human Arginase 1 (hArg1) is a metalloenzyme that catalyzes the hydrolysis of l-arginine to l-ornithine and urea, and modulates T-cell-mediated immune response. Arginase-targeted therapies have been pursued across several disease areas including immunology, oncology, nervous system dysfunction, and cardiovascular dysfunction and diseases. Currently, all published hArg1 inhibitors are small molecules usually less than 350Da in size. Here we report the cryo-electron microscopy structures of potent and inhibitory anti-hArg antibodies bound to hArg1 which form distinct macromolecular complexes that are greater than 650kDa. With local resolutions of 3.5 angstrom or better we unambiguously mapped epitopes and paratopes for all five antibodies and determined that the antibodies act through orthosteric and allosteric mechanisms. These hArg1:antibody complexes present an alternative mechanism to inhibit hArg1 activity and highlight the ability to utilize antibodies as probes in the discovery and development of peptide and small molecule inhibitors for enzymes in general. Palte et al provide cryo-EM structures of five potent and inhibitory monoclonal antibodies bound to human Arginase 1, a T-cell modulating metalloenzyme and a cancer drug target. They provide structural insights that will aid in the evaluation of these antibodies as therapeutic inhibitors of arginasemediated T-cell suppression.

Automated summary

Palte et al. present cryo-EM structures of five potent and inhibitory monoclonal antibodies bound to human Arginase 1, showcasing an alternative mechanism for inhibiting hArg1 activity through orthosteric and allosteric mechanisms. The structural insights provided will aid in evaluating these antibodies as potential therapeutic inhibitors for arginase-mediated T-cell suppression.